The Food and Drug Administration is set to expedite its assessment of psychedelic drugs created by Compass Pathways, the Usona Institute, and Transcend Therapeutics aimed at treating mental health disorders. This initiative is part of the Trump administration’s strategy to enhance access to these controversial but potentially beneficial treatments.
The agency plans to issue priority review vouchers for Compass’ psilocybin treatment for depression unresponsive to other therapies, Usona’s similar drug for major depressive disorder, and Transcend’s MDMA-like therapy for post-traumatic stress disorder.
Although the FDA revealed the specific medications receiving these vouchers, it did not disclose the developers. However, Compass, Usona, and Transcend have confirmed they were granted vouchers.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
